Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2022 07:00 ET | Source: Passage Bio

Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestones, for Cohort 1 patients in Imagine-1 clinical trial for GM1 gangliosidosisDosed first...
March 01, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming March Investor Conferences

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
February 24, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
February 11, 2022 11:00 ET | Source: Passage Bio

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregiversInterim safety...
January 31, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11Podium presentations on clinical trial designs for...
January 10, 2022 07:00 ET | Source: Passage Bio

Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline

Present longer follow-up and clinical milestones for Cohort 1 of the Imagine-1 GM1 gangliosidosis clinical trial at the 18th Annual WORLDSymposium, February 11, 2022Dose first patients in Cohorts 2...
January 03, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
December 17, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious...
December 08, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Exercised two additional options with University of Pennsylvania’s Gene Therapy Program aligned with company’s focus on CNS diseases with high unmet need Huntington’s disease, a fatal rare adult...
November 19, 2021 16:00 ET | Source: Passage Bio

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...